Global Artificial Tears Market research

Artificial Tears Comprehensive Study by Type (Artificial Tear Liquid, Artificial Tear Ointment), Application (Dry Eyes Treatment, Contact Lenses Moisten, Others), End User (Hospital, Clinic, Other) Players and Region - Global Market Outlook to 2028

Artificial Tears Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Artificial Tears Market?

Artificial tears is refer as the lubricant eye drops which is used for treatment of the dryness and irritation associated with the deficient tear production in keratoconjunctivitis sicca which is commonly called as dry eyes. They are also popularly used for moisten the contact lenses and also in testing the eye. Artificial tears also help in maintaining the moisture on the outer surface of the eye. This kind of eye drop is also used to treat eyes that results from ageing, a medical condition, certain medications, eye surgery or environmental factors, like smoky or windy conditions. Artificial tears can be available in the market without any prescription. some of the artificial tears contain electrolytes. These kind of additives may promote healing of the eye surface. Artificial tears may also contain thickening agents, which keeps the solution on the eye surface for longer period

Highlights from Artificial Tears Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledAllergan (Republic of Ireland), Alcon (Novartis) (United States), Bausch & Lomb (United States), Abbott (United States), Santen Pharmaceutical (Japan), Ursapharm (Germany), Rohto (Japan), Similasan Corporation (United States), Johnson & Johnson (United States) and Ocusoft (United States)


The Artificial Tears market is a fragmented market due to the presence of a large number of established competitors. The market is highly competitive with a few players occupying the major share. The key players are highly focused on developing and innovating new strategies to maintain their market position and customer base. The companies are also planning strategic activities like partnerships, collaboration, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge. Research Analyst at AMA predicts that United States and Chinese Players will contribute to the maximum growth of Global Artificial Tears market throughout the forecasted period.

Allergan (Republic of Ireland), Alcon (Novartis) (United States), Bausch & Lomb (United States), Abbott (United States), Santen Pharmaceutical (Japan), Ursapharm (Germany), Rohto (Japan), Similasan Corporation (United States), Johnson & Johnson (United States) and Ocusoft (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Nicox (France), Wuhan Yuanda (China) and Jiangxi Zhenshiming (China).

Artificial Tears Market Segmentation:
ScopeSub-Segments
Application / End UserDry Eyes Treatment, Contact Lenses Moisten and Others
TypeArtificial Tear Liquid and Artificial Tear Ointment
End UserHospital,Clinic,Other


On the basis of geography, the market of Artificial Tears has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising in the phacoemulsification surgeries

Market Growth Drivers:
Growing incidences of dry eye syndrome and Prolonged emission to the blue light causing eye damage

Challenges:
Newly effective treatment for DES

Restraints:
Side effect such as red eyes irritation, eye pain, vision changes and other allergic reactions and High cost associated with the product costing

Opportunities:
Untapped Emerging Markets

Key Target Audience
Artificial tears producers, Artificial tears suppliers, Artificial tears retailers and wholesalers, Pharmaceuticals, Research firms and Healthcare industry

Market Leaders & Development Strategies
Alcon, the global leader in eye care and a division of Novartis, announced that it has acquired Tear Film Innovations, Inc. (“Tear Film”), a privately-held company and manufacturer of the iLux Device, an innovative therapeutic device used to treat Meibomian Gland Dysfunction, a leading cause of dry eye
Alcon, the global leader in eye care and a division of Novartis, recently launched a new website, AlconScience.com, for US- and Canada-based Eye Care Professionals (ECPs) and academic institutions. The new Medical Affairs website consolidates information about Alcon’s scientific, academic, and related activities into one portal


Report Objectives / Segmentation Covered

By Type
  • Artificial Tear Liquid
  • Artificial Tear Ointment
By Application
  • Dry Eyes Treatment
  • Contact Lenses Moisten
  • Others
By End User
  • Hospital
  • Clinic
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing incidences of dry eye syndrome
      • 3.2.2. Prolonged emission to the blue light causing eye damage
    • 3.3. Market Challenges
      • 3.3.1. Newly effective treatment for DES
    • 3.4. Market Trends
      • 3.4.1. Rising in the phacoemulsification surgeries
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Artificial Tears, by Type, Application, End User and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Artificial Tears (Value)
      • 5.2.1. Global Artificial Tears by: Type (Value)
        • 5.2.1.1. Artificial Tear Liquid
        • 5.2.1.2. Artificial Tear Ointment
      • 5.2.2. Global Artificial Tears by: Application (Value)
        • 5.2.2.1. Dry Eyes Treatment
        • 5.2.2.2. Contact Lenses Moisten
        • 5.2.2.3. Others
      • 5.2.3. Global Artificial Tears by: End User (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Clinic
        • 5.2.3.3. Other
      • 5.2.4. Global Artificial Tears Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Artificial Tears: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Allergan (Republic of Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alcon (Novartis) (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bausch & Lomb (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Abbott (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Santen Pharmaceutical (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ursapharm (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Rohto (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Similasan Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Johnson & Johnson (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Ocusoft (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Artificial Tears Sale, by Type, Application, End User and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Artificial Tears (Value)
      • 7.2.1. Global Artificial Tears by: Type (Value)
        • 7.2.1.1. Artificial Tear Liquid
        • 7.2.1.2. Artificial Tear Ointment
      • 7.2.2. Global Artificial Tears by: Application (Value)
        • 7.2.2.1. Dry Eyes Treatment
        • 7.2.2.2. Contact Lenses Moisten
        • 7.2.2.3. Others
      • 7.2.3. Global Artificial Tears by: End User (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Clinic
        • 7.2.3.3. Other
      • 7.2.4. Global Artificial Tears Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Artificial Tears: by Type(USD Million)
  • Table 2. Artificial Tears Artificial Tear Liquid , by Region USD Million (2017-2022)
  • Table 3. Artificial Tears Artificial Tear Ointment , by Region USD Million (2017-2022)
  • Table 4. Artificial Tears: by Application(USD Million)
  • Table 5. Artificial Tears Dry Eyes Treatment , by Region USD Million (2017-2022)
  • Table 6. Artificial Tears Contact Lenses Moisten , by Region USD Million (2017-2022)
  • Table 7. Artificial Tears Others , by Region USD Million (2017-2022)
  • Table 8. Artificial Tears: by End User(USD Million)
  • Table 9. Artificial Tears Hospital , by Region USD Million (2017-2022)
  • Table 10. Artificial Tears Clinic , by Region USD Million (2017-2022)
  • Table 11. Artificial Tears Other , by Region USD Million (2017-2022)
  • Table 12. South America Artificial Tears, by Country USD Million (2017-2022)
  • Table 13. South America Artificial Tears, by Type USD Million (2017-2022)
  • Table 14. South America Artificial Tears, by Application USD Million (2017-2022)
  • Table 15. South America Artificial Tears, by End User USD Million (2017-2022)
  • Table 16. Brazil Artificial Tears, by Type USD Million (2017-2022)
  • Table 17. Brazil Artificial Tears, by Application USD Million (2017-2022)
  • Table 18. Brazil Artificial Tears, by End User USD Million (2017-2022)
  • Table 19. Argentina Artificial Tears, by Type USD Million (2017-2022)
  • Table 20. Argentina Artificial Tears, by Application USD Million (2017-2022)
  • Table 21. Argentina Artificial Tears, by End User USD Million (2017-2022)
  • Table 22. Rest of South America Artificial Tears, by Type USD Million (2017-2022)
  • Table 23. Rest of South America Artificial Tears, by Application USD Million (2017-2022)
  • Table 24. Rest of South America Artificial Tears, by End User USD Million (2017-2022)
  • Table 25. Asia Pacific Artificial Tears, by Country USD Million (2017-2022)
  • Table 26. Asia Pacific Artificial Tears, by Type USD Million (2017-2022)
  • Table 27. Asia Pacific Artificial Tears, by Application USD Million (2017-2022)
  • Table 28. Asia Pacific Artificial Tears, by End User USD Million (2017-2022)
  • Table 29. China Artificial Tears, by Type USD Million (2017-2022)
  • Table 30. China Artificial Tears, by Application USD Million (2017-2022)
  • Table 31. China Artificial Tears, by End User USD Million (2017-2022)
  • Table 32. Japan Artificial Tears, by Type USD Million (2017-2022)
  • Table 33. Japan Artificial Tears, by Application USD Million (2017-2022)
  • Table 34. Japan Artificial Tears, by End User USD Million (2017-2022)
  • Table 35. India Artificial Tears, by Type USD Million (2017-2022)
  • Table 36. India Artificial Tears, by Application USD Million (2017-2022)
  • Table 37. India Artificial Tears, by End User USD Million (2017-2022)
  • Table 38. South Korea Artificial Tears, by Type USD Million (2017-2022)
  • Table 39. South Korea Artificial Tears, by Application USD Million (2017-2022)
  • Table 40. South Korea Artificial Tears, by End User USD Million (2017-2022)
  • Table 41. Taiwan Artificial Tears, by Type USD Million (2017-2022)
  • Table 42. Taiwan Artificial Tears, by Application USD Million (2017-2022)
  • Table 43. Taiwan Artificial Tears, by End User USD Million (2017-2022)
  • Table 44. Australia Artificial Tears, by Type USD Million (2017-2022)
  • Table 45. Australia Artificial Tears, by Application USD Million (2017-2022)
  • Table 46. Australia Artificial Tears, by End User USD Million (2017-2022)
  • Table 47. Rest of Asia-Pacific Artificial Tears, by Type USD Million (2017-2022)
  • Table 48. Rest of Asia-Pacific Artificial Tears, by Application USD Million (2017-2022)
  • Table 49. Rest of Asia-Pacific Artificial Tears, by End User USD Million (2017-2022)
  • Table 50. Europe Artificial Tears, by Country USD Million (2017-2022)
  • Table 51. Europe Artificial Tears, by Type USD Million (2017-2022)
  • Table 52. Europe Artificial Tears, by Application USD Million (2017-2022)
  • Table 53. Europe Artificial Tears, by End User USD Million (2017-2022)
  • Table 54. Germany Artificial Tears, by Type USD Million (2017-2022)
  • Table 55. Germany Artificial Tears, by Application USD Million (2017-2022)
  • Table 56. Germany Artificial Tears, by End User USD Million (2017-2022)
  • Table 57. France Artificial Tears, by Type USD Million (2017-2022)
  • Table 58. France Artificial Tears, by Application USD Million (2017-2022)
  • Table 59. France Artificial Tears, by End User USD Million (2017-2022)
  • Table 60. Italy Artificial Tears, by Type USD Million (2017-2022)
  • Table 61. Italy Artificial Tears, by Application USD Million (2017-2022)
  • Table 62. Italy Artificial Tears, by End User USD Million (2017-2022)
  • Table 63. United Kingdom Artificial Tears, by Type USD Million (2017-2022)
  • Table 64. United Kingdom Artificial Tears, by Application USD Million (2017-2022)
  • Table 65. United Kingdom Artificial Tears, by End User USD Million (2017-2022)
  • Table 66. Netherlands Artificial Tears, by Type USD Million (2017-2022)
  • Table 67. Netherlands Artificial Tears, by Application USD Million (2017-2022)
  • Table 68. Netherlands Artificial Tears, by End User USD Million (2017-2022)
  • Table 69. Rest of Europe Artificial Tears, by Type USD Million (2017-2022)
  • Table 70. Rest of Europe Artificial Tears, by Application USD Million (2017-2022)
  • Table 71. Rest of Europe Artificial Tears, by End User USD Million (2017-2022)
  • Table 72. MEA Artificial Tears, by Country USD Million (2017-2022)
  • Table 73. MEA Artificial Tears, by Type USD Million (2017-2022)
  • Table 74. MEA Artificial Tears, by Application USD Million (2017-2022)
  • Table 75. MEA Artificial Tears, by End User USD Million (2017-2022)
  • Table 76. Middle East Artificial Tears, by Type USD Million (2017-2022)
  • Table 77. Middle East Artificial Tears, by Application USD Million (2017-2022)
  • Table 78. Middle East Artificial Tears, by End User USD Million (2017-2022)
  • Table 79. Africa Artificial Tears, by Type USD Million (2017-2022)
  • Table 80. Africa Artificial Tears, by Application USD Million (2017-2022)
  • Table 81. Africa Artificial Tears, by End User USD Million (2017-2022)
  • Table 82. North America Artificial Tears, by Country USD Million (2017-2022)
  • Table 83. North America Artificial Tears, by Type USD Million (2017-2022)
  • Table 84. North America Artificial Tears, by Application USD Million (2017-2022)
  • Table 85. North America Artificial Tears, by End User USD Million (2017-2022)
  • Table 86. United States Artificial Tears, by Type USD Million (2017-2022)
  • Table 87. United States Artificial Tears, by Application USD Million (2017-2022)
  • Table 88. United States Artificial Tears, by End User USD Million (2017-2022)
  • Table 89. Canada Artificial Tears, by Type USD Million (2017-2022)
  • Table 90. Canada Artificial Tears, by Application USD Million (2017-2022)
  • Table 91. Canada Artificial Tears, by End User USD Million (2017-2022)
  • Table 92. Mexico Artificial Tears, by Type USD Million (2017-2022)
  • Table 93. Mexico Artificial Tears, by Application USD Million (2017-2022)
  • Table 94. Mexico Artificial Tears, by End User USD Million (2017-2022)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Artificial Tears: by Type(USD Million)
  • Table 106. Artificial Tears Artificial Tear Liquid , by Region USD Million (2023-2028)
  • Table 107. Artificial Tears Artificial Tear Ointment , by Region USD Million (2023-2028)
  • Table 108. Artificial Tears: by Application(USD Million)
  • Table 109. Artificial Tears Dry Eyes Treatment , by Region USD Million (2023-2028)
  • Table 110. Artificial Tears Contact Lenses Moisten , by Region USD Million (2023-2028)
  • Table 111. Artificial Tears Others , by Region USD Million (2023-2028)
  • Table 112. Artificial Tears: by End User(USD Million)
  • Table 113. Artificial Tears Hospital , by Region USD Million (2023-2028)
  • Table 114. Artificial Tears Clinic , by Region USD Million (2023-2028)
  • Table 115. Artificial Tears Other , by Region USD Million (2023-2028)
  • Table 116. South America Artificial Tears, by Country USD Million (2023-2028)
  • Table 117. South America Artificial Tears, by Type USD Million (2023-2028)
  • Table 118. South America Artificial Tears, by Application USD Million (2023-2028)
  • Table 119. South America Artificial Tears, by End User USD Million (2023-2028)
  • Table 120. Brazil Artificial Tears, by Type USD Million (2023-2028)
  • Table 121. Brazil Artificial Tears, by Application USD Million (2023-2028)
  • Table 122. Brazil Artificial Tears, by End User USD Million (2023-2028)
  • Table 123. Argentina Artificial Tears, by Type USD Million (2023-2028)
  • Table 124. Argentina Artificial Tears, by Application USD Million (2023-2028)
  • Table 125. Argentina Artificial Tears, by End User USD Million (2023-2028)
  • Table 126. Rest of South America Artificial Tears, by Type USD Million (2023-2028)
  • Table 127. Rest of South America Artificial Tears, by Application USD Million (2023-2028)
  • Table 128. Rest of South America Artificial Tears, by End User USD Million (2023-2028)
  • Table 129. Asia Pacific Artificial Tears, by Country USD Million (2023-2028)
  • Table 130. Asia Pacific Artificial Tears, by Type USD Million (2023-2028)
  • Table 131. Asia Pacific Artificial Tears, by Application USD Million (2023-2028)
  • Table 132. Asia Pacific Artificial Tears, by End User USD Million (2023-2028)
  • Table 133. China Artificial Tears, by Type USD Million (2023-2028)
  • Table 134. China Artificial Tears, by Application USD Million (2023-2028)
  • Table 135. China Artificial Tears, by End User USD Million (2023-2028)
  • Table 136. Japan Artificial Tears, by Type USD Million (2023-2028)
  • Table 137. Japan Artificial Tears, by Application USD Million (2023-2028)
  • Table 138. Japan Artificial Tears, by End User USD Million (2023-2028)
  • Table 139. India Artificial Tears, by Type USD Million (2023-2028)
  • Table 140. India Artificial Tears, by Application USD Million (2023-2028)
  • Table 141. India Artificial Tears, by End User USD Million (2023-2028)
  • Table 142. South Korea Artificial Tears, by Type USD Million (2023-2028)
  • Table 143. South Korea Artificial Tears, by Application USD Million (2023-2028)
  • Table 144. South Korea Artificial Tears, by End User USD Million (2023-2028)
  • Table 145. Taiwan Artificial Tears, by Type USD Million (2023-2028)
  • Table 146. Taiwan Artificial Tears, by Application USD Million (2023-2028)
  • Table 147. Taiwan Artificial Tears, by End User USD Million (2023-2028)
  • Table 148. Australia Artificial Tears, by Type USD Million (2023-2028)
  • Table 149. Australia Artificial Tears, by Application USD Million (2023-2028)
  • Table 150. Australia Artificial Tears, by End User USD Million (2023-2028)
  • Table 151. Rest of Asia-Pacific Artificial Tears, by Type USD Million (2023-2028)
  • Table 152. Rest of Asia-Pacific Artificial Tears, by Application USD Million (2023-2028)
  • Table 153. Rest of Asia-Pacific Artificial Tears, by End User USD Million (2023-2028)
  • Table 154. Europe Artificial Tears, by Country USD Million (2023-2028)
  • Table 155. Europe Artificial Tears, by Type USD Million (2023-2028)
  • Table 156. Europe Artificial Tears, by Application USD Million (2023-2028)
  • Table 157. Europe Artificial Tears, by End User USD Million (2023-2028)
  • Table 158. Germany Artificial Tears, by Type USD Million (2023-2028)
  • Table 159. Germany Artificial Tears, by Application USD Million (2023-2028)
  • Table 160. Germany Artificial Tears, by End User USD Million (2023-2028)
  • Table 161. France Artificial Tears, by Type USD Million (2023-2028)
  • Table 162. France Artificial Tears, by Application USD Million (2023-2028)
  • Table 163. France Artificial Tears, by End User USD Million (2023-2028)
  • Table 164. Italy Artificial Tears, by Type USD Million (2023-2028)
  • Table 165. Italy Artificial Tears, by Application USD Million (2023-2028)
  • Table 166. Italy Artificial Tears, by End User USD Million (2023-2028)
  • Table 167. United Kingdom Artificial Tears, by Type USD Million (2023-2028)
  • Table 168. United Kingdom Artificial Tears, by Application USD Million (2023-2028)
  • Table 169. United Kingdom Artificial Tears, by End User USD Million (2023-2028)
  • Table 170. Netherlands Artificial Tears, by Type USD Million (2023-2028)
  • Table 171. Netherlands Artificial Tears, by Application USD Million (2023-2028)
  • Table 172. Netherlands Artificial Tears, by End User USD Million (2023-2028)
  • Table 173. Rest of Europe Artificial Tears, by Type USD Million (2023-2028)
  • Table 174. Rest of Europe Artificial Tears, by Application USD Million (2023-2028)
  • Table 175. Rest of Europe Artificial Tears, by End User USD Million (2023-2028)
  • Table 176. MEA Artificial Tears, by Country USD Million (2023-2028)
  • Table 177. MEA Artificial Tears, by Type USD Million (2023-2028)
  • Table 178. MEA Artificial Tears, by Application USD Million (2023-2028)
  • Table 179. MEA Artificial Tears, by End User USD Million (2023-2028)
  • Table 180. Middle East Artificial Tears, by Type USD Million (2023-2028)
  • Table 181. Middle East Artificial Tears, by Application USD Million (2023-2028)
  • Table 182. Middle East Artificial Tears, by End User USD Million (2023-2028)
  • Table 183. Africa Artificial Tears, by Type USD Million (2023-2028)
  • Table 184. Africa Artificial Tears, by Application USD Million (2023-2028)
  • Table 185. Africa Artificial Tears, by End User USD Million (2023-2028)
  • Table 186. North America Artificial Tears, by Country USD Million (2023-2028)
  • Table 187. North America Artificial Tears, by Type USD Million (2023-2028)
  • Table 188. North America Artificial Tears, by Application USD Million (2023-2028)
  • Table 189. North America Artificial Tears, by End User USD Million (2023-2028)
  • Table 190. United States Artificial Tears, by Type USD Million (2023-2028)
  • Table 191. United States Artificial Tears, by Application USD Million (2023-2028)
  • Table 192. United States Artificial Tears, by End User USD Million (2023-2028)
  • Table 193. Canada Artificial Tears, by Type USD Million (2023-2028)
  • Table 194. Canada Artificial Tears, by Application USD Million (2023-2028)
  • Table 195. Canada Artificial Tears, by End User USD Million (2023-2028)
  • Table 196. Mexico Artificial Tears, by Type USD Million (2023-2028)
  • Table 197. Mexico Artificial Tears, by Application USD Million (2023-2028)
  • Table 198. Mexico Artificial Tears, by End User USD Million (2023-2028)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Artificial Tears: by Type USD Million (2017-2022)
  • Figure 5. Global Artificial Tears: by Application USD Million (2017-2022)
  • Figure 6. Global Artificial Tears: by End User USD Million (2017-2022)
  • Figure 7. South America Artificial Tears Share (%), by Country
  • Figure 8. Asia Pacific Artificial Tears Share (%), by Country
  • Figure 9. Europe Artificial Tears Share (%), by Country
  • Figure 10. MEA Artificial Tears Share (%), by Country
  • Figure 11. North America Artificial Tears Share (%), by Country
  • Figure 12. Global Artificial Tears share by Players 2022 (%)
  • Figure 13. Global Artificial Tears share by Players (Top 3) 2022(%)
  • Figure 14. Global Artificial Tears share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Allergan (Republic of Ireland) Revenue, Net Income and Gross profit
  • Figure 17. Allergan (Republic of Ireland) Revenue: by Geography 2022
  • Figure 18. Alcon (Novartis) (United States) Revenue, Net Income and Gross profit
  • Figure 19. Alcon (Novartis) (United States) Revenue: by Geography 2022
  • Figure 20. Bausch & Lomb (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bausch & Lomb (United States) Revenue: by Geography 2022
  • Figure 22. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 23. Abbott (United States) Revenue: by Geography 2022
  • Figure 24. Santen Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Santen Pharmaceutical (Japan) Revenue: by Geography 2022
  • Figure 26. Ursapharm (Germany) Revenue, Net Income and Gross profit
  • Figure 27. Ursapharm (Germany) Revenue: by Geography 2022
  • Figure 28. Rohto (Japan) Revenue, Net Income and Gross profit
  • Figure 29. Rohto (Japan) Revenue: by Geography 2022
  • Figure 30. Similasan Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 31. Similasan Corporation (United States) Revenue: by Geography 2022
  • Figure 32. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 33. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 34. Ocusoft (United States) Revenue, Net Income and Gross profit
  • Figure 35. Ocusoft (United States) Revenue: by Geography 2022
  • Figure 36. Global Artificial Tears: by Type USD Million (2023-2028)
  • Figure 37. Global Artificial Tears: by Application USD Million (2023-2028)
  • Figure 38. Global Artificial Tears: by End User USD Million (2023-2028)
  • Figure 39. South America Artificial Tears Share (%), by Country
  • Figure 40. Asia Pacific Artificial Tears Share (%), by Country
  • Figure 41. Europe Artificial Tears Share (%), by Country
  • Figure 42. MEA Artificial Tears Share (%), by Country
  • Figure 43. North America Artificial Tears Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Allergan (Republic of Ireland)
  • Alcon (Novartis) (United States)
  • Bausch & Lomb (United States)
  • Abbott (United States)
  • Santen Pharmaceutical (Japan)
  • Ursapharm (Germany)
  • Rohto (Japan)
  • Similasan Corporation (United States)
  • Johnson & Johnson (United States)
  • Ocusoft (United States)
Additional players considered in the study are as follows:
Nicox (France) , Wuhan Yuanda (China) , Jiangxi Zhenshiming (China)
Select User Access Type

Key Highlights of Report


Apr 2023 214 Pages 62 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Artificial Tears Market research Quantitative research analysis
Global Artificial Tears Market research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Growing incidences of dry eye syndrome " is seen as one of major growth factors of Artificial Tears Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Artificial Tears market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Artificial Tears Market research Report?

Have a Query? Click Here

Other Related Reports

Archwire Comprehensive Study by Type (Nickel Titanium Archwire, Thermal Nickel Titanium Archwire, Copper Nickel Titanium Archwire, Beta Titanium Archwire, Stainless Steel Archwire, Coated Nickel Tita...
$ 3750
Baby Nipples Comprehensive Study by Type (Thumb-type Baby Nipples, Spiral Baby Nipples), Application (Newborn, 3-6 Months Old, >6 Months Old), Sales Channel (Online Sales, Offline Sales) Players and ...
$ 3500
Cannabis Oil Comprehensive Study by Type (Organic, Non-Organic), Application (Recreational, Medical), Components (Cannabidiol (CBD), Delta-9 Tetrahydrocannabinol (THC)) Players and Region - Global Ma...
$ 3500
Clinical Nutrition Comprehensive Study by Type (Oral Nutrition, Enteral Nutrition, Parenteral Nutrition), Application (Infant and Child, Adults, Geriatrics), Category (Micronutrients, Macronutrients)...
$ 3800
Powder Free Gloves Comprehensive Study by Type (Disposable, Reusable), Application (Sterile Laboratory, Treatment Room, Hospitals, Food Service, Othe), Distribution Channel (Pharmacies, Drug Stores, ...
$ 3650
Calcium Citrate Comprehensive Study by Application (Food & Beverage, Pharmaceutical, Others), Form (Micronized Powder, Powder, Granular), Grade (Food Grade, Pharmaceutical Grade) Players and Region -...
$ 3500